^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    COX2 inhibitor

    Related drugs:
    15h
    Celecoxib in Parkinson Disease as Adjuvant Therapy (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Tanta University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    celecoxib oral
    8d
    Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression. (PubMed, J Immunother Cancer)
    PCSK9 promoted HCC immune escape by upregulating SPP1 and PD-L1 via NOTCH3/FLI1 signaling. CRISPR ABE-mediated PCSK9 deficiency and PCSK9 inhibitor parecoxib may serve as effective strategies to inhibit HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • NOTCH3 (Notch Receptor 3) • SPP1 (Secreted Phosphoprotein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    PD-L1 expression
    |
    Dynastat (parecoxib)
    12d
    Celecoxib in Parkinson Disease as Adjuvant Therapy (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Tanta University
    New P1/2 trial
    |
    celecoxib oral
    16d
    Crowned dens syndrome combined with cervical disc herniation: A case report and literature review. (PubMed, Medicine (Baltimore))
    CDS should be considered in cases of acute pain in the neck or occipital regions. Moreover, prompt computed tomography of the cervical vertebrae may guide early diagnosis and avoid unnecessary invasive procedures or administration of antibiotics.
    Review • Journal
    |
    CRP (C-reactive protein)
    |
    celecoxib oral
    17d
    VRPAIN: Virtual Reality for Pain and Anxiety Relief During Peripheral Angioplasty (clinicaltrials.gov)
    P2/3, N=52, Completed, Kastamonu University | Not yet recruiting --> Completed
    Trial completion
    |
    midazolam hydrochloride
    19d
    Decoding intratumoral cyclooxygenase-2 signaling through multi-omics: insights from esophageal cancer and beyond. (PubMed, Clin Exp Med)
    This study underscored COX-2 as a critical regulator of inflammatory microenvironment and cancer progression in ESCA, supporting its potential as both a prognostic biomarker and therapeutic target. The use of COX-2 inhibitors, such as celecoxib, holds promise for improving patient outcomes in ESCA and other COX-2-associated cancers.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL17A (Interleukin 17A)
    |
    celecoxib oral
    23d
    TNF-α inhibitor etanercept improves cerebrovascular function in elderly RA patients: findings from a randomized controlled trial. (PubMed, BMC Rheumatol)
    The TNF-α inhibitor Etanercept significantly improves cerebral hemodynamics and cerebrovascular reserve function in elderly RA patients, potentially by suppressing systemic inflammation and improving vascular endothelial function.
    Journal
    |
    IL6 (Interleukin 6) • IL1B (Interleukin 1, beta) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CRP (C-reactive protein)
    |
    methotrexate • celecoxib oral
    24d
    Synthesis of novel pyrazole derivatives and neuroprotective effect investigation. (PubMed, J Enzyme Inhib Med Chem)
    Notable, compound 6g exhibited better inhibitory potency against IL-6 expression compared to the anti-inflammatory drugs dexamethasone and Celecoxib. These findings strongly support the potential of compound 6g as a promising therapeutic candidate for mitigating secondary inflammation in SCI.
    Journal
    |
    IL6 (Interleukin 6) • IL1B (Interleukin 1, beta)
    |
    dexamethasone • celecoxib oral
    1m
    Identification and Verification of Immune Metabolism-Related Biomarkers and Immune Infiltration Landscape for Pediatric Opsoclonus Myoclonus Ataxia Syndrome in Neuroblastoma. (PubMed, CNS Neurosci Ther)
    Four immune metabolism-associated diagnostic genes were identified, including TRAF3IP2, RIPK1, KEAP1, and DPP4 for OMAS.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    1m
    Neuroinflammation in Patients With OCD (clinicaltrials.gov)
    P2, N=21, Suspended, New York State Psychiatric Institute | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    celecoxib oral